Baird analyst David Rescott raised the firm’s price target on Nyxoah to $13.03 from $5.49 and keeps a Neutral rating on the shares. The firm saiid they see significant revenue inflection ahead as the company enters the large and underpenetrated US OSA market opportunity estimated around 2025 despite remaining hurdles.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NYXH:
- Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
- Is NYXH a Buy, Before Earnings?
- Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
- Nyxoah price target raised to $18 from $15 at H.C. Wainwright
- Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
